| # | Title | Journal | Year | Citations |
|---|
| 1 | Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma | New England Journal of Medicine | 2011 | 4,074 |
| 2 | Principles of early drug discovery | British Journal of Pharmacology | 2011 | 1,689 |
| 3 | New use of BCG for recombinant vaccines | Nature | 1991 | 1,467 |
| 4 | Toll-like receptor 9–dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE | Nature Immunology | 2007 | 1,210 |
| 5 | Tackling antibiotic resistance | Nature Reviews Microbiology | 2011 | 919 |
| 6 | American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials | Arthritis and Rheumatism | 2011 | 864 |
| 7 | Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer | Journal of Clinical Oncology | 2016 | 755 |
| 8 | Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma | JAMA Oncology | 2017 | 750 |
| 9 | A bacterial genome in flux: the twelve linear and nine circular extrachromosomal DNAs in an infectious isolate of the Lyme disease spirochete Borrelia burgdorferi | Molecular Microbiology | 2002 | 730 |
| 10 | Alternatives to antibiotics—a pipeline portfolio review | Lancet Infectious Diseases, The | 2016 | 720 |
| 11 | Mast cells are essential intermediaries in regulatory T-cell tolerance | Nature | 2006 | 688 |
| 12 | Anifrolumab, an Anti–Interferon‐α Receptor Monoclonal Antibody, in Moderate‐to‐Severe Systemic Lupus Erythematosus | Arthritis and Rheumatology | 2017 | 634 |
| 13 | Development of a Humanized Monoclonal Antibody (MEDI‐493) with Potent In Vitro and In Vivo Activity against Respiratory Syncytial Virus | Journal of Infectious Diseases | 1997 | 587 |
| 14 | X-ray Structure of the FimC-FimH Chaperone-Adhesin Complex from Uropathogenic Escherichia coli | Science | 1999 | 582 |
| 15 | Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study | Lancet Oncology, The | 2016 | 556 |
| 16 | Validation of immunoassays for bioanalysis: a pharmaceutical industry perspective | Journal of Pharmaceutical and Biomedical Analysis | 2000 | 527 |
| 17 | Contribution of novel choline‐binding proteins to adherence, colonization and immunogenicity of Streptococcus pneumoniae | Molecular Microbiology | 1997 | 446 |
| 18 | Innate IL-13–producing nuocytes arise during allergic lung inflammation and contribute to airways hyperreactivity | Journal of Allergy and Clinical Immunology | 2012 | 446 |
| 19 | Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study | Lancet Respiratory Medicine,the | 2014 | 435 |
| 20 | Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial | Lancet, The | 2019 | 433 |
| 21 | Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study | Annals of the Rheumatic Diseases | 2016 | 420 |
| 22 | Transfer of HIV-1-specific cytotoxic T lymphocytes to an AIDS patient leads to selection for mutant HIV variants and subsequent disease progression | Nature Medicine | 1995 | 372 |
| 23 | Receptor binding studies disclose a novel class of high-affinity inhibitors of the Escherichia coli FimH adhesin | Molecular Microbiology | 2004 | 372 |
| 24 | Structural basis of tropism of Escherichia coli to the bladder during urinary tract infection | Molecular Microbiology | 2002 | 360 |
| 25 | Inflammatory triggers associated with exacerbations of COPD orchestrate plasticity of group 2 innate lymphoid cells in the lungs | Nature Immunology | 2016 | 357 |
| 26 | Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway | Annals of the Rheumatic Diseases | 2011 | 341 |
| 27 | IL-9 as a mediator of Th17-driven inflammatory disease | Journal of Experimental Medicine | 2009 | 334 |
| 28 | A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma | European Respiratory Journal | 2013 | 334 |
| 29 | CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade | Cancer Discovery | 2018 | 323 |
| 30 | Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial | Lancet Respiratory Medicine,the | 2015 | 318 |
| 31 | Noncanonical Autophagy Is Required for Type I Interferon Secretion in Response to DNA-Immune Complexes | Immunity | 2012 | 315 |
| 32 | Increasing the Affinity of a Human IgG1 for the Neonatal Fc Receptor: Biological Consequences | Journal of Immunology | 2002 | 307 |
| 33 | Vaccination with FimH Adhesin Protects Cynomolgus Monkeys from Colonization and Infection by UropathogenicEscherichia coli | Journal of Infectious Diseases | 2000 | 301 |
| 34 | IL-1 is a critical regulator of group 2 innate lymphoid cell function and plasticity | Nature Immunology | 2016 | 295 |
| 35 | Treatment of atopic dermatitis with tralokinumab, an anti–IL-13 mAb | Journal of Allergy and Clinical Immunology | 2019 | 294 |
| 36 | A Systematic Review of Risk Factors Associated with Surgical Site Infections among Surgical Patients | PLoS ONE | 2013 | 290 |
| 37 | Real-Time Reverse Transcriptase PCR Assay for Detection of Human Metapneumoviruses from All Known Genetic Lineages | Journal of Clinical Microbiology | 2004 | 284 |
| 38 | Effectiveness of School-Based Influenza Vaccination | New England Journal of Medicine | 2006 | 281 |
| 39 | A Novel Investigational Fc-Modified Humanized Monoclonal Antibody, Motavizumab-YTE, Has an Extended Half-Life in Healthy Adults | Antimicrobial Agents and Chemotherapy | 2013 | 275 |
| 40 | Type I Interferon: Potential Therapeutic Target for Psoriasis? | PLoS ONE | 2008 | 260 |
| 41 | Neutralization of interferon‐α/β–inducible genes and downstream effect in a phase I trial of an anti–interferon‐α monoclonal antibody in systemic lupus erythematosus | Arthritis and Rheumatism | 2009 | 257 |
| 42 | The Immunoscore: Colon Cancer and Beyond | Clinical Cancer Research | 2020 | 255 |
| 43 | Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study | Lancet Respiratory Medicine,the | 2014 | 248 |
| 44 | Respiratory syncytial virus-coded pediatric hospitalizations, 1997 to 1999 | Pediatric Infectious Disease Journal | 2002 | 239 |
| 45 | Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn’s Disease: A Phase 2a Study | Gastroenterology | 2017 | 232 |
| 46 | Benznidazole and Posaconazole in Eliminating Parasites in Asymptomatic T. Cruzi Carriers | Journal of the American College of Cardiology | 2017 | 231 |
| 47 | Early, transient depletion of plasmacytoid dendritic cells ameliorates autoimmunity in a lupus model | Journal of Experimental Medicine | 2014 | 229 |
| 48 | MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study | Lancet, The | 2018 | 227 |
| 49 | Glycosylation at 158N of the Hemagglutinin Protein and Receptor Binding Specificity Synergistically Affect the Antigenicity and Immunogenicity of a Live Attenuated H5N1 A/Vietnam/1203/2004 Vaccine Virus in Ferrets | Journal of Virology | 2010 | 224 |
| 50 | Persistence of Morbidity and Cost Differences Between Late-Preterm and Term Infants During the First Year of Life | Pediatrics | 2009 | 223 |
